CDMO Enteris BioPharma has changed its name to MOD3 Pharma.
The wholly owned subsidiary of SWK Holdings has rebranded to relflect the refocusing of its service portfolio.
MOD3 Pharma will now place its primary focus on customers developing orally inhaled and nasal drug products (OINDP) — specifically those in early phase clinical trials.
The company can offer semi-automated filling and assembly for single dose powder and liquid nasal systems, as well as multidose devices and spray drying capabilities.
By providing clients with a clinical supply, the CDMO hopes to fill the market gap for smaller production volumes with fast turnaround times.
“Enteris BioPharma built its reputation by formulating peptide drugs as oral tablets, enabling innovative treatment opportunities for compounds that typically were delivered via another route," noted Dr Paul Shields, CEO of MOD3 Pharma.
“In recent years we have utilised our expertise and experience to support several clients navigating Phase 1&2 clinical trials in the OINDP space; especially for nasal sprays and, increasingly, nasal powders. As we've become a prevalent figurehead in this scene, it made perfect sense to create a new name that better reflects our core competencies," he continued.
“MOD3 Pharma is the catalyst to clinic, and we're here to help companies complete Module 3 of your IND — its in our name," Dr Shields concluded.